Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer

PURPOSE: Triple-negative breast cancer (TNBC) lacks the receptor targets estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, and thus it does not respond to receptor-targeted treatments. TNBC has higher recurrence, metastasis, and mortality rates than other subtyp...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Breast Cancer Res Treat
Auteurs principaux: Lee, Jangsoon, Lim, Bora, Pearson, Troy, Choi, Kuicheon, Fuson, Jon A., Bartholomeusz, Chandra, Paradiso, Linda J., Myers, Thomas, Tripathy, Debu, Ueno, Naoto T.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534477/
https://ncbi.nlm.nih.gov/pubmed/30826934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-019-05166-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires